Hello,
There have been plenty of discussions on the forums about gransnetters’ experiences of the menopause and the support your encountered from health professionals whilst going through it.
The National Institute for Health and Clincal Excellence (NICE) has now put together draft guidelines about Menopause: diagnosis and management which they would really value your thoughts on.
This is your opportunity to put forward your views and experiences and possibly influence NICE guidelines in this area going forward. If you would like to comment please read through the draft guidelines NICE has provided and if you can, make a note in your comment on the numbered paragraph you are referring to.
If you’d prefer to remain anonymous but still want to contribute please email [email protected] with 'Menopause' in the subject.
Here is more information from NICE:
Professor Mark Baker, Centre for Clinical Practice Director at NICE, said: “Menopause affects millions of women, and its symptoms can severely upset a woman’s day to day life. The effects of menopause are often misunderstood and underestimated – it can result in problems ranging from hot flushes to brittle bones, joint stiffness and cardiovascular disease.
“When women seek medical help for their symptoms, there is considerable variation in what is offered to them. So NICE is pleased to be developing the first guideline for the NHS on diagnosing and managing menopause, to help improve the lives of women affected by it.”
Draft recommendations include which tests can be used to diagnose menopause, and advice on offering holistic, individualised care that takes into account the woman’s symptoms and preferences. The draft guideline also highlights that clinicians should give support and advice to women who are likely to go through menopause as a result of medical or surgical treatment, including women with cancer, at high risk of hormone-dependent cancer or having gynaecological surgery. To help women and clinicians decide on what approaches are right for each individual, drug and non-drug treatment options are covered. This includes draft recommendations based on the benefits and risks of treatment with HRT, with specific information provided for women in various clinical circumstances. For example, it’s often considered that women at risk of hypertension or other cardiovascular conditions should not take HRT, but the draft recommendations propose that they shouldn’t automatically be prevented from taking it.
NICE welcomes comments from stakeholders on the draft recommendations as part of our public consultation.
Draft recommendations include:
• Diagnose the following without laboratory tests in otherwise healthy women aged over 45 years with menopausal symptoms:
o perimenopause (the lead up to menopause) based on vasomotor symptoms (like hot flushes) and irregular periods
o menopause in women who have not had a period for at least 12 months
o menopause based on symptoms in women without a uterus (womb)
• Offer holistic, individualised care that takes into account the woman’s symptoms and preferences. Give information to menopausal women and their family members or carers (as appropriate) that includes:
o an explanation of the stages of menopause
o common symptoms and diagnosis
o lifestyle changes and interventions that could help general health and wellbeing
o the benefits and risks of treatments for menopausal symptoms.
• Consider cognitive behavioural therapy (CBT) for alleviation of low mood and anxiety in menopausal women
• Ensure that menopausal women and healthcare professionals involved in their care understand that HRT:
o does not increase cardiovascular disease risk when started in women aged under 60 years
o does not affect the risk of dying from cardiovascular disease
• Ensure that menopausal women and healthcare professionals involved in their care understand that HRT does not affect the risk of dying from breast cancer, and explain to women that:
o that HRT with oestrogen alone is associated with little or no increase in the risk of breast cancer, but that HRT with oestrogen and progestogen can be associated with an increase in the risk of breast cancer
o any increase in risk of breast cancer is related to treatment duration and reduces after stopping HRT.